Product Pipeline

The Small Molecule Therapeutics Segment is a small-molecule drug development business, with a pipeline of product candidates leveraging the discovery of two receptors involved in the regulation of the healing process. PBI-4050, the small molecules lead drug candidate has demonstrated excellent safety, tolerability and efficacy profiles in a large number of animal models of fibrosis affecting different organs, including the lung, liver, heart, kidney, and pancreas. The effects of PBI-4050 demonstrated in animal models have been replicated in Phase 2 clinical studies in IPF, in metabolic syndrome with type 2 diabetes and in Alström syndrome. PBI-4050 is entering pivotal placebo-controlled phase 3 clinical trials for the treatment of IPF.

The Plasma-derived Therapeutics Segment includes our plasma-derived therapeutics platform, which enables the development of our pipeline of biopharmaceutical candidates. This is achieved by leveraging our proprietary affinity technology, which enables a highly-efficient extraction and purification process of therapeutic proteins from human plasma. The Corporation’s primary focus is to develop plasma-derived therapeutics targeting unmet medical conditions and rare diseases in both established and emerging markets.

Our Priority Indications

Clear Filter
Subscribe
Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
PBI-4050
Idiopathic Pulmonary Fibrosis
PBI-4050
Alström Syndrome
Ryplazim™ IV
Congenital Deficiency
Ryplazim™ IV
Acute Deficiency
IVIG
Primary Immunodeficiency Diseases

Other Products in Development

Clear Filter
Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
PBI-4547
Nonalcoholic Steatohepatitis (NASH)
Plasminogen Sc
Diabetic Foot Ulcer
Plasminogen Sc
Tympanic Membrane Perforation
Inter Alpha Inhibitor Protein (IAIP)
Necrotizing Enterocolitis